Our studies, to the best of our knowledge, indicate an epigenetic mechanism for the activation of PI3K and suggest that RAD21 might be a suitable indicator for the use of PI3K inhibitors in patients with NSCLC. The gene discussed is RAD21; the disease is non-small cell lung carcinoma.